Annora Pharma Private Limited Atorvastatin Export Data — India (DGFT 2022–2026)

Name: Annora Pharma Private Limited Atorvastatin Export Records India — #15 Exporter, 426 Shipments, $8.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Atorvastatin

India Pharmaceutical Trade Intelligence

$1.1B477 Suppliers145 CountriesHS 30049099

ExportsIndia → UNITED STATES52.5%India → CANADA25.9%

ImportsCROATIA → India$3.5M CANADA → India$2.5M

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: APOTEX CORP

Annora Pharma Private Limited — Atorvastatin Exporter #15 | $8.4M Trade Value | TransData Nexus | TransData Nexus

Annora Pharma Private Limited — Atorvastatin Exporter Profile

Indian Pharmaceutical Exporter · #15 for Atorvastatin · $8.4M export value · DGFT Verified

Annora Pharma Private Limited is the #15 Indian exporter of Atorvastatin with $8.4M in export value and 426 verified shipments. Annora Pharma Private Limited holds a 0.8% market share in Atorvastatin exports across 1 countries. The company exports 13 pharmaceutical products worth $56.8M across 9 therapeutic categories.

Annora Pharma Private Limited — Atorvastatin Export Profile: Buyers & Destinations

Annora Pharma Private Limited Atorvastatin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Atorvastatin?

Country	Value	Shipments	Share
UNITED STATES	$194.4M	3,889	50.4%
MALTA	$32.5M	1,226	8.4%
UNITED KINGDOM	$30.2M	1,243	7.8%
CANADA	$29.4M	587

Who Are the Top Buyers of Atorvastatin from India?

Buyer	Country	Value	Orders
APL SWIFT SERVICES (MALTA) LTD.,	MALTA	$25.9M	517
APOTEX CORP	UNITED STATES	$21.4M	429
NOVADOZ PHARMACEUTICALS LLC	UNITED STATES	$17.3M	549
BIOCON PHARMA INC	UNITED STATES	$16.0M	339
YUSEN LOGISTICS BENELUX BELGIUM	BELGIUM	$14.7M	663
LIFESCIENCE LOGISTICS	UNITED STATES	$6.7M	133
MYLAN PHARMACEUTICALS INC,	UNITED STATES	$5.0M	99
ACCORD HEALTHCARE INC.,	CANADA	$850.0K	17
BIOMEDPHARMA	CANADA	$800.0K	16
ASCEND LABOATORIES,LLC C/O UPS	UNITED STATES	$150.0K	3

India's Atorvastatin is purchased by 1,291 buyers worldwide. The top buyer is APL SWIFT SERVICES (MALTA) LTD., (MALTA), followed by APOTEX CORP and NOVADOZ PHARMACEUTICALS LLC.

How Does Annora Pharma Private Limited Compare to Nearest Atorvastatin Exporters?

Exporters ranked immediately above and below #15 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	UMEDICA LABORATORIES PRIVATE LIMITED	$11.8M	235	8	$50.0K
12	BIOCON PHARMA LIMITED	$11.4M	229	2	$50.0K
15	ANNORA PHARMA PRIVATE LIMITED ★	$8.4M	426	1	$19.7K
14	APOTEX RESEARCH PRIVATE LIMITED	$6.2M	124	1	$50.0K
13	JUBILANT GENERICS LIMITED	$5.8M	115	1	$50.0K

Annora Pharma Private Limited ranks #15 among 477 Indian Atorvastatin exporters. Average shipment value of $19.7K compared to the market average of $657.7K. The closest competitors by value are UMEDICA LABORATORIES PRIVATE LIMITED and BIOCON PHARMA LIMITED.

Which Indian Ports Ship Atorvastatin Exports?

Port	Shipments	% Share
HYDERABAD ICD	2,042	13.6%
HYDERABAD ICD (INSNF6)	1,131	7.5%
NHAVA SHEVA SEA (INNSA1)	842	5.6%
SAHAR AIR	839	5.6%
JNPT/ NHAVA SHEVA SEA	779	5.2%
DELHI AIR	613	4.1%
SAHAR AIR CARGO ACC (INBOM4)	581	3.9%
HYDERABAD AIR	554	3.7%

Geopolitical & Trade Policy Impact on Annora Pharma Private Limited's Atorvastatin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Annora Pharma. The Israel-Iran conflict has led to disruptions in the Red Sea shipping routes, causing maritime carriers to suspend bookings and reroute vessels around the Cape of Good Hope. These changes have resulted in increased lead times and freight costs, disproportionately affecting time-sensitive pharmaceutical shipments. The Pharmaceutical Export Promotion Council of India (Pharmexcil) estimates potential losses ranging from ₹2,500 crore to ₹5,000 crore due to these disruptions. (fortuneindia.com)

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. With the U.S. imposing tariffs on Chinese goods, Indian exporters have an opportunity to capture a larger share of the American market. However, this advantage is tempered by the U.S. administration's pressure on pharmaceutical companies to lower drug prices and the potential for increased tariffs on imported pharmaceuticals, which could impact profit margins. (lemonde.fr)

In the European Union, the implementation of the Falsified Medicines Directive (FMD) has introduced stringent regulations aimed at preventing counterfeit drugs from entering the supply chain. Compliance with these regulations requires significant investment in serialization and traceability systems. For companies like Annora Pharma, adhering to these standards is crucial to maintain access to the lucrative EU market.

Annora Pharma Private Limited — Regulatory Compliance & Quality Standards

Regulatory compliance remains a critical factor for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has intensified inspections of Indian manufacturing facilities, with over 200 inspections conducted in 2023 and plans to increase this number in 2024. Non-compliance can lead to warning letters, import alerts, and bans, severely impacting export capabilities. (fact.net.in)

Annora Pharma's involvement in a patent infringement lawsuit with BioCryst Pharmaceuticals highlights the importance of navigating intellectual property rights carefully. Ensuring that generic products do not infringe on existing patents is essential to avoid legal disputes that can delay market entry and result in financial liabilities.

Maintaining high-quality standards and adhering to Good Manufacturing Practices (GMP) are imperative for sustaining credibility and competitiveness in international markets. Investing in robust quality control systems and staying abreast of evolving regulatory requirements will be key for Annora Pharma's continued success.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Atorvastatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Annora Pharma Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 145+ countries, 1,291+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Atorvastatin

Atorvastatin

Annora Pharma Private Limited — Atorvastatin Exporter Profile

Annora Pharma Private Limited — Atorvastatin Export Profile: Buyers & Destinations

Where Does India Export Atorvastatin?

Who Are the Top Buyers of Atorvastatin from India?

What Is India's Total Atorvastatin Export Value and How Much Does Annora Pharma Private Limited Contribute?

What Is the Average Shipment Value for Annora Pharma Private Limited's Atorvastatin Exports?

How Does Annora Pharma Private Limited Compare to Other Indian Atorvastatin Exporters?

Regulatory Requirements: Exporting Atorvastatin to Key Markets

United States — FDA

United Kingdom — MHRA

How Does Annora Pharma Private Limited Compare to Nearest Atorvastatin Exporters?

Which Indian Ports Ship Atorvastatin Exports?

What Other Cardiovascular Products Does Annora Pharma Private Limited Export?

Geopolitical & Trade Policy Impact on Annora Pharma Private Limited's Atorvastatin Exports

Annora Pharma Private Limited — Regulatory Compliance & Quality Standards

About Annora Pharma Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Atorvastatin Export Data from Annora Pharma Private Limited

Atorvastatin Stats

Company Overview

Top Products by Annora Pharma Private Limited

Related Analysis

Need Detailed Export Data?

Data Source